Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Comparison of GP IIB/IIIA inhibitors and their activity as measured by aggregometry, flow cytometry, single platelet counting, and the rapid plateletfunction analyzer
Autore:
Matzdorff, AC; Kuhnel, G; Kemkes-Matthes, B; Voss, R;
Indirizzi:
Univ Giessen, Fac Internal Med, Ctr Internal Med, Dept Hematol Oncol, D-35385 Giessen, Germany Univ Giessen Giessen Germany D-35385 tol Oncol, D-35385 Giessen, Germany
Titolo Testata:
JOURNAL OF THROMBOSIS AND THROMBOLYSIS
fascicolo: 2, volume: 12, anno: 2001,
pagine: 129 - 139
SICI:
0929-5305(200110)12:2<129:COGIIA>2.0.ZU;2-E
Fonte:
ISI
Lingua:
ENG
Soggetto:
PERCUTANEOUS CORONARY INTERVENTION; PLASMINOGEN-ACTIVATOR; UNSTABLE ANGINA; INTERNAL POOL; WHOLE-BLOOD; RECEPTOR; ABCIXIMAB; ANTAGONISTS; AGGREGATION; BLOCKADE;
Keywords:
GP IIb/IIIa-inhibitor; aggregometry; Rapid Platelet Function Analyzer; flow cytometry;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Citazioni:
33
Recensione:
Indirizzi per estratti:
Indirizzo: Matzdorff, AC Univ Giessen, Fac Internal Med, Ctr Internal Med, Dept Hematol Oncol, KlinStr 36, D-35385 Giessen, Germany Univ Giessen Klin Str 36 Giessen Germany D-35385 n, Germany
Citazione:
A.C. Matzdorff et al., "Comparison of GP IIB/IIIA inhibitors and their activity as measured by aggregometry, flow cytometry, single platelet counting, and the rapid plateletfunction analyzer", J THROMB TH, 12(2), 2001, pp. 129-139

Abstract

Background: GP IIb/IIIa inhibitors have primarily been used short-term e.g., during PTCA. They failed to show clinical benefit during long-term therapy. One reason might be the absence of a method to monitor inhibitor activity. This study compared platelet aggregometry, the rapid platelet function analyzer (RPFA) test, single platelet counting, and flow cytometric determination of receptor occupancy to measure GP IIb/IIIa-receptor inhibitor activity. Methods: Increasing doses of abciximab, tirofiban, and eptifibatide were added to whole blood in vitro. Whole blood was used for the RPFA, for singleplatelet counting and flow cytometry. Platelet rich plasma was prepared for aggregometry. Results: The correlation between aggregometry and RPFA results was linear for abciximab and eptifibatide. Tirofiban was a stronger inhibitor with theRPFA (IC50 7.7 nM) than with aggregometry (IC50 19.6 nM). The single platelet counting technique showed that even supratherapeutic concentrations of all three inhibitors could not completely suppress microaggregation. Abciximab concentrations that were equipotent to tirofiban with aggregometry wereless potent with regards to the inhibition of microaggregation. This difference was more pronounced with TRAP induced microaggregation than with ADP. The flow cytometric receptor occupancy test showed that occupancy was 95% with 5 mug/ml abciximab and almost 97% with 10 mug/ml. Tirofiban reached a maximum receptor occupancy of 56%, eptifibatide 64%. Conclusions: While aggregometry is time consuming the RPFA provides results fast and with little variability. There is still a discrepancy between aggregometry and RPFA results for tirofiban. The single platelet counting technique detects the inhibition of microaggregation the relevance of which for the clinical outcome is not known. The flow cytometric receptor occupancyassay is best suited for abciximab.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 08/04/20 alle ore 09:04:55